Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.
The objective of this study is to observe the long-term effect of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on thromboprophylaxis, and establish a foundation of evidence for managing patients with high-risk VTE.

Start Date01 Nov 2024

Sponsor / Collaborator

Navy General Hospital

100 Clinical Results associated with Navy General Hospital

0 Patents (Medical) associated with Navy General Hospital

1,489

Literatures (Medical) associated with Navy General Hospital

01 Aug 2024·Respiratory Medicine

Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia

Article

Author: Jin, Zhang ; Park, Hae-Sim ; Xiuhua, Fu ; Mao, Huang ; Min, Chen ; Min, Zhang ; Åstrand, Annika ; Canmao, Xie ; Wei, Gu ; Jie, Li ; Kewu, Huang ; Hye-Kyung, Park ; Longju, Zhang ; Shih, Vivian H ; Liangping, Mao ; Woo, Kim Jin ; Lijun, Chen ; Cohen, David ; Ruoran, Li ; Meiling, Jin ; Zheng, Wenying ; Limin, Wang ; Minjing, Li ; Huiyu, Lu ; Sang-Ha, Kim ; Jison, Maria ; Xiaoxia, Liu ; Haihong, Wu ; Zuke, Xiao ; Yi, Xiao ; Ping, Chen ; Xiyuan, Xu ; Mei, Chen ; Zhimin, Chen ; Yanming, Li ; Sim, Park Hae ; Diahn-Warng, Perng ; Grace Dawn, Isidro Marie ; Jianping, Yan ; Xianhua, Li ; Chun-Hua, Wang ; Joo, Yoon Ho ; Shengxi, Ma ; Chuntao, Liu ; Hongzhong, Yang ; Jianping, Zhao ; Debin, Sun ; Yingqun, Zhu ; Jianping, Bo ; Guangfa, Wang ; Wei, Han ; Hoon, Min Kyung ; Sun, Dejun ; Ziwen, Zhao ; Jiulong, Kuang ; Mingyan, Jiang ; Zhong, Nanshan ; Yao, Yuhui ; Luning, Jiang ; Chuanhe, Liu ; Chih-Feng, Chian ; Dejun, Sun ; Yong, Lim Seong ; Bi, Chen ; Xiwen, Gao ; Wei, Zhang ; Jian, Kang ; Ronnie, Samoro ; Sook, Cho You ; Liping, Wei ; Zhang, Yajuan ; Zhuang, Luo ; Xingxiang, Xu ; Samoro, Ronnie ; Jung-Won, Park ; Guochao, Shi ; Werkström, Viktoria ; Lai, Kefang ; Jin-Fu, Xu ; Xiaoli, Zhu ; Shanping, Jiang ; Choon-Sik, Park ; Wen, Li ; Inbeom, Jeong ; Xuefen, Wang ; Zhihai, Han ; Wei, Hu Xi ; Wencheng, Yu ; Ping-Hung, Kuo ; Lin, Mu ; Dai, Ranran ; Albert, Albay ; Yan, Wang ; Manxiang, Li ; Jing, Liu

BACKGROUNDBenralizumab is indicated as add-on therapy in patients with uncontrolled, severe eosinophilic asthma; it has not yet been evaluated in a large Asian population with asthma in a clinical trial.OBJECTIVETo evaluate the efficacy and safety of benralizumab in patients with severe asthma in Asia.METHODSMIRACLE (NCT03186209) was a randomized, Phase 3 study in China, South Korea, and the Philippines. Patients aged 12-75 years with severe asthma receiving medium-to-high-dose inhaled corticosteroid/long-acting β₂-agonists, stratified (2:1) by baseline blood eosinophil count (bEOS) (≥300/μL; <300/μL), were randomized (1:1) to benralizumab 30 mg or placebo. Endpoints included annual asthma exacerbation rate (AAER; primary endpoint), change from baseline at Week 48 in pre-bronchodilator (BD) forced expiratory volume in 1 second (pre-BD FEV₁) and total asthma symptom score (TASS). Safety was evaluated ≤ Week 56.RESULTSOf 695 patients randomized, 473 had baseline bEOS ≥300/μL (benralizumab n = 236; placebo n = 237). In this population, benralizumab significantly reduced AAER by 74% (rate ratio 0.26 [95% CI 0.19, 0.36], p < 0.0001) and significantly improved pre-BD FEV₁ (least squares difference [LSD] 0.25 L [95% CI 0.17, 0.34], p < 0.0001) and TASS (LSD -0.25 [-0.45, -0.05], p = 0.0126) versus placebo. In patients with baseline bEOS <300/μL, there were numerical improvements in AAER, pre-BD FEV₁, and TASS with benralizumab versus placebo. The frequency of adverse events was similar for benralizumab (76%) and placebo (80%) in the overall population.CONCLUSIONSMIRACLE data reinforces the efficacy and safety of benralizumab for severe eosinophilic asthma in an Asian population, consistent with the global Phase 3 results.

01 Jan 2023·Frontiers in oncology

Gene mutation landscape of a rare patient with acute megakaryoblastic leukemia after treatment of intracranial germ cell tumor.

Article

Author: Liao, Wei-Jie ; Jiang, Yu-Hua ; Lu, Wang-Sheng ; Chen, Chao ; Wang, Li-Xin ; Yin, Feng ; Ning, Hao-Yong

IntroductionIt was first reported that germ cell tumor patients suffer from hematologic malignancies 37 years ago. Since then, the number of relevant reports has increased each year, with most cases being mediastinal germ cell tumor. Theories have been proposed to explain this phenomenon, including a shared origin of progenitor cells, the effects of treatment, and independent development. However, up to now, no widely accepted explanation exists. The case with acute megakaryoblastic leukemia and intracranial germ cell tumor has never been reported before and the association is far less known.MethodsWe used whole exome sequencing and gene mutation analysis to study the relationship between intracranial germ cell tumor and acute megakaryoblastic leukemia of our patient.ResultsWe report a patient who developed acute megakaryoblastic leukemia after treatment for an intracranial germ cell tumor. Through whole exome sequencing and gene mutation analysis, we identified that both tumors shared the same mutation genes and mutation sites, suggesting they originated from the same progenitor cells and differentiated in the later stage.DiscussionOur findings provide the first evidence supporting the theory that acute megakaryoblastic leukemia and intracranial germ cell tumor has the same progenitor cells.

01 Jan 2022·Therapeutic Advances in HematologyQ2 · MEDICINE

Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study

Q2 · MEDICINE

ArticleOA

Author: Hu, Jian-Da ; Yang, Lin-Hua ; Shen, Xu-Liang ; Liu, Kai-Yan ; Zhan, Si-Yan ; Wang, Qian-Fei ; Chang, Ying-Jun ; Yin, Cheng-Hong ; Zhang, Xiao-Hui ; Xu, Lan-Ping ; Qian, Shen-Xian ; Huang, Ren-Wei ; Zhu, Xiao-Lu ; Liu, Hui-Xin ; Wang, Jian-Liu ; Liang, Mei-Ying ; Liu, Yi ; Yao, Hong-Xia ; Huang, Xiao-Jun ; Jiang, Zhong-Xing ; Liu, Hui ; Huang, Qiu-Sha ; Jiang, Ming ; Wang, Xing-Lin ; Xiao, Zhen ; Feng, Ru ; Zhang, Xiao-Hong ; Zhang, Jing-Yu ; Zhang, Lei ; Wang, Yu ; Wang, Jing-Wen ; Kong, Yuan ; Li, Yue-Ying ; Yang, Tong-Hua ; Zhang, Hong-Yu

Background: The responses of intravenous immunoglobulin (IVIg) or corticosteroids as the initial treatment on pregnancy with ITP were unsatisfactory. This study aimed to assess the safety and effectiveness of prednisone plus IVIg versus prednisone or IVIg in pregnant patients with immune thrombocytopenia (ITP). Methods: Between 1 January 2010 and 31 December 2020, 970 pregnancies diagnosed with ITP at 19 collaborative centers in China were reviewed in this observational study. A total of 513 pregnancies (52.89%) received no intervention. Concerning the remaining pregnancies, 151 (33.04%) pregnancies received an initial treatment of prednisone plus IVIg, 105 (22.98%) pregnancies received IVIg alone, and 172 (37.64%) pregnancies only received prednisone. Results: Regarding the maternal response to the initial treatment, no differences were found among the three treatment groups (41.1% for prednisone plus IVIg, 33.1% for prednisone, and 38.1% for IVIg). However, a significant difference was observed in the time to response between the prednisone plus IVIg group (4.39 ± 2.54 days) and prednisone group (7.29 ± 5.01 days; p < 0.001), and between the IVIg group (6.71 ± 4.85 days) and prednisone group ( p < 0.001). The median prednisone duration in the monotherapy group was 27 days (range, 8–195 days), whereas that in the combination group was 14 days (range, 6–85 days). No significant differences were found among these three treatment groups in neonatal outcomes, particularly concerning the neonatal platelet counts. The time to response in the combination treatment group was shorter than prednisone monotherapy. The duration of prednisone application in combination group was shorter than prednisone monotherapy. The combined therapy showed a lower predelivery platelet transfusion rate than IVIg alone. Conclusion: These findings suggest that prednisone plus IVIg may represent a potential combination therapy for pregnant patients with ITP.

100 Deals associated with Navy General Hospital

100 Translational Medicine associated with Navy General Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Navy General Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 22 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing